We Cover the Latest News in Economy  Politics  States  Indigenous  Foreign affairs  Business  Defence  Immigration  Local news 

LATEST NEWS
TRENDING NEWS
FOREIGN AFFAIRS
White House defends drug price maths

White House defends drug price maths that breaks the rules of arithmetic

Trump and Kennedy doubled their stance on how prescription drug costs had been decreased to hundreds of per cent, which is mathematically impossible and has led to further investigation from members of parliament as well as fact checkers.

While answering the queries put forth to him at the hearing by Senator Warren from Massachusetts during an appearance he made at the Senate Finance Committee.

Kennedy was asked why the drugs on the TrumpRx website offered discounts as high as 600%, saying that they would essentially mean that companies are now paying people for taking drugs.

Instead of correcting the mistake, Kennedy gave a justification of his statement.

Kennedy said that the President calculates percentages in a totally different way and that a reduction from 600 dollars to 10 dollars was 600%.

It has nothing to do with mathematics and even the most liberal calculation says it is 98%. A discount can never reach more than 100%, because then it would become free of cost.

The next day, while addressing the press inside the Oval Office, Kennedy returned to his previous comments about percentages on his own accord.

The senator remarked that while a hike from $100 to $600 in the price of a drug amounts to a sixfold or 600% increase, a decrease from $600 to $100 should likewise be considered a savings.

A mathematical method of such a nature does not exist. Although it is possible for prices to increase more than once there cannot be a price decrease by a number larger than one as it will result in negative pricing.

Even Trump came to the aid of his campaign, recognizing that although he had mentioned reductions of “500%, 600%,” he often makes use of “50%, 60%.”

This type of calculation, Trump explained, represents a different way of calculating. It was an explanation Trump has made consistently after unveiling his drug pricing plan through TrumpRx earlier this year.

It came at the expense of what the White House intended to be an important statement regarding its drug pricing policy.

The new Regeneron deal is the 17th most favored nations’ pact made with a big pharmaceutical company.

They are firms that represent 86% of the total branded drug market.

Also Read: ‘Not a get rich quick scheme’: Parliament passes sweeping NDIS fraud laws

According to the agreement, Regeneron agreed to reduce the cost of its cholesterol medicine, Praluent, from $537 to $225 for individuals buying under TrumpRX and also committed to investing $27 billion in research and development in America by 2029.

This is not the only dubious number thrown in during the discussion that caught the eye of many people.

There is another one where he claimed the conflict with Iran, which began on 28 February and had already gone past seven and a half weeks, was still within the predicted period of four to six weeks.

Another one that has always come up in every speech he makes since he was inaugurated was the issue of the size of his inaugural gathering.

While the drug pricing agreements proposed by the administration have been questioned by the Democratic members regarding the effectiveness of such agreements for the people.

MORE TOP HEADLINES
JUST IN
RECOMMENDED FOR YOU ​
Apple's first foldable iPhone

Apple’s first foldable iPhone edges closer signals 2026 launch

Apple’s foldable iPhone, which had been speculated upon for almost a decade now, seems to have been confirmed beyond doubt, after recent developments and leaks indicated the possibility of an iPhone that could redefine the future of high end smartphones.

Foxconn, one of Apple’s manufacturers, has reportedly started trial production of the device.

This comes from Chinese leaker Instant Digital. Trial production represents the stage just before manufacturing and Apple plans to commence mass production in July, provided there are no hitches at the current stage of manufacture.

The confirmation came after reports from Nikkei Asia suggested that manufacturing issues might cause the device to miss out on its launch date.

When leaker Sonny Dickson shared pictures of dummy models for the foldable iPhone next to the iPhone 18 Pro and iPhone 18 Pro Max, it was probably the most obvious sign.

Accessory makers often use dummy units, which are non functional prototypes, to get ready for cases and other products before an official announcement.

The leaked dummies showed that the device is much wider and shorter when closed than most Android foldables from Samsung or Google.

The inner display will be about 7.8 inches wide and have a resolution of 2,713 1,920 pixels.

The outer screen will be about 5.5 inches wide. The aspect ratio is likely to be 4:3, which makes the proportions more like those of an iPad mini than a smartphone.

It is said that Apple was very keen on making an iPhone with a crease free display.

Also reported that Samsung will provide the OLED panels, as Apple aims to give it a longevity of 300,000 folds.

As an alternative, Apple will be offering its Touch ID technology, which will be available through its power button as in the latest iPad Air series.

The name of the product is yet unclear, but rumours claim that it will be called iPhone Ultra and not iPhone Fold.

Also Read: Netflix Quietly Cancelled the Zayn and Louis Series

This way, Apple aims to create its new premium range of products, and according to analysts, it will cost between $2,000 and $2,500.

There is, however, some uncertainty about the launch date.

Gurman has also said that it will probably be available a little later than the Pro models.

Originally, mass production was supposed to start in June, but it has been pushed back to August. MingChi Kuo an Apple analyst has warned that problems with production could lead to supply shortages that last until 2027.

The question is not whether Apple will produce such a phone, but rather when they’ll produce one.

The more pertinent question for those considering buying one is whether the hefty price tag makes them first in line worth it.

INSIDE FIELD